FDA approved Arexvy for the prevention of RSV LRTD in adults 50 through 59 years of age who are at increased risk
GSK announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk. In…